FDA Approves New Parkinson's Disease Treatment from AbbVie
The U.S. FDA has approved AbbVie's JUVMO (tavapadon) tablets, a selective D1/D5 receptor agonist, for adults with Parkinson's disease. This approval marks a significant advancement in dopaminergic treatments for the progressive neurological disorder, offering a new therapeutic option for patients.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.